biopharmaceutical Archives | Page 2 of 2

Home / Posts tagged biopharmaceutical (Page 2)

RedHill Biopharma Reports 2016 Fourth Quarter and Full-Year Financial Results

TEL-AVIV, Israel, Feb. 23 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today reported its financial results for the fourth quarter and full-year ended December [...]

RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis

TEL-AVIV, Israel,, Feb. 13 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced enrollment of the last patient in the Phase III study with [...]

Samsung BioLogics Suffers Loss in 2016

SEOUL, Jan. 24 (Korea Bizwire) – Samsung BioLogics, a biopharmaceutical unit of South Korea’s top conglomerate Samsung Group, suffered a loss last year despite a sharp rise in sales, the company said Tuesday. Sales more than tripled to 295 billion won (US$252.6 million) in 2016 from 91.28 billion the previous year, the company said in [...]

Korean Biotech Firms Embrace Open Innovation

SEOUL, July 20 (Korea Bizwire) – ‘Open innovation’ refers to a company’s innovative means to develop a new product or service by sharing and accepting new knowledge and ideas from other companies or start-ups that have developed groundbreaking technology. The practice is becoming increasingly common in the Korean pharmaceutical and biotechnology industries. In the past, innovations were [...]

Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement

NEW YORK & SEOUL, South Korea, Apr. 22, 2014 (Korea Bizwire) – Bristol-Myers Squibb Company (NYSE:BMY) and Samsung BioLogics announced the companies will increase the scope of their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its Incheon manufacturing site. Financial terms of the [...]